{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:40:02Z","timestamp":1792194002950,"version":"4.4.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016619","name":"MyoKardia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["ZE 1109\/1-1"],"award-info":[{"award-number":["ZE 1109\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jacc.2019.11.031","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T15:59:21Z","timestamp":1580140761000},"page":"422-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":535,"title":["Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter\u00a02\u00a0Inhibitors"],"prefix":"10.1016","volume":"75","author":[{"given":"Thomas A.","family":"Zelniker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.11.031_bib1","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1001\/jama.2014.3201","article-title":"Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009","volume":"311","author":"Dabelea","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.11.031_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jama.2016.8544","article-title":"Prevalence of diabetes in adolescents aged 12 to 19 Years in the United States, 2005-2014","volume":"316","author":"Menke","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.11.031_bib3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF Diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacc.2019.11.031_bib4","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.031_bib5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fendo.2018.00613","article-title":"The discovery of insulin: an important milestone in the history of medicine","volume":"9","author":"Vecchio","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2019.11.031_bib6","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.031_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of\u00a0cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.11.031_bib11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2019.11.031_bib12","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.031_bib13","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC State-of-the-Art Review","volume":"72","author":"Zelniker","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.031_bib14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00424-003-1202-0","article-title":"The sodium\/glucose cotransport family SLC5","volume":"447","author":"Wright","year":"2004","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.jacc.2019.11.031_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2019.11.031_bib16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/dbi18-0007","article-title":"Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease","volume":"68","author":"Alicic","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2019.11.031_bib17","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.031_bib18","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","article-title":"Molecular analysis of the SGLT2 gene in patients with renal glucosuria","volume":"14","author":"Santer","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2019.11.031_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target","volume":"5","author":"Santer","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2019.11.031_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2019.11.031_bib21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.diabres.2017.11.016","article-title":"Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment","volume":"135","author":"Horie","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacc.2019.11.031_bib22","doi-asserted-by":"crossref","first-page":"123130","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacc.2019.11.031_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2019.11.031_bib24","doi-asserted-by":"crossref","first-page":"16113","DOI":"10.1038\/s41598-018-34305-x","article-title":"A\u00a0reduced M1-like\/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition","volume":"8","author":"Miyachi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2019.11.031_bib25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pcad.2019.07.003","article-title":"Diabetes, heart failure, and renal dysfunction: The vicious circles","volume":"62","author":"Braunwald","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2019.11.031_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart failure in type 2 diabetes mellitus","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2019.11.031_bib27","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2019.11.031_bib28","first-page":"e294","article-title":"Type 2 diabetes mellitus and heart failure: A Scientific Statement From the American Heart Association and the Heart\u00a0Failure Society of America","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.031_bib29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","article-title":"Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy","volume":"71","author":"Marwick","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.031_bib30","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/CIRCRESAHA.118.314665","article-title":"Diabetic cardiomyopathy","volume":"124","author":"Dillmann","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2019.11.031_bib31","first-page":"436","article-title":"Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.031_bib32","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s12325-016-0457-8","article-title":"Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus","volume":"34","author":"Tanaka","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacc.2019.11.031_bib33","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2019.11.031_bib34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2019.11.031_bib35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12933-017-0654-z","article-title":"SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial","volume":"17","author":"Karg","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2019.11.031_bib36","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1681\/ASN.2016060662","article-title":"Skin Sodium concentration correlates with left ventricular hypertrophy in CKD","volume":"28","author":"Schneider","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2019.11.031_bib37","article-title":"24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: Results from the randomized, placebo-controlled SACRA study","author":"Kario","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.031_bib38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.031_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacc.2019.11.031_bib40","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jacc.2019.11.031_bib41","article-title":"Glucose metabolism in cardiac hypertrophy and heart failure","volume":"8","author":"Tran","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2019.11.031_bib42","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3389\/fphys.2019.00639","article-title":"Metabolic profiling of the diabetic heart: Toward a richer picture","volume":"10","author":"Sowton","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacc.2019.11.031_bib43","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2019.11.031_bib44","doi-asserted-by":"crossref","first-page":"12407","DOI":"10.1172\/jci.insight.124079","article-title":"The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense","volume":"4","author":"Horton","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacc.2019.11.031_bib45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2019.11.031_bib46","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nonndiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.031_bib47","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2019.02.023","article-title":"SGLT2 inhibition: Changing what fuels the heart","volume":"73","author":"Lehrke","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.031_bib48","first-page":"575","article-title":"Empagliflozin increases cardiac energy production in diabetes: Novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Basic Transl Sci"},{"key":"10.1016\/j.jacc.2019.11.031_bib49","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/dom.13536","article-title":"Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized (13) C magnetic resonance spectroscopy study","volume":"21","author":"Abdurrachim","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2019.11.031_bib50","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/cvr\/cvz104","article-title":"Ketone body can be a fuel substrate for failing heart","volume":"115","author":"Nakamura","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2019.11.031_bib51","first-page":"15","article-title":"SGLT2 Inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart","volume":"4","author":"Lim","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Basic Transl Sci"},{"key":"10.1016\/j.jacc.2019.11.031_bib52","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease","volume":"21","author":"Maruyama","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jacc.2019.11.031_bib53","doi-asserted-by":"crossref","first-page":"107402","DOI":"10.1016\/j.jdiacomp.2019.06.007","article-title":"Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: a post hoc analysis of 10 randomized, placebo-controlled trials","author":"Toto","year":"2019","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.jacc.2019.11.031_bib54","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1161\/CIRCULATIONAHA.113.008476","article-title":"Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients","volume":"130","author":"Montaigne","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.031_bib55","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","article-title":"Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients","volume":"9","author":"Uthman","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacc.2019.11.031_bib56","article-title":"Biomarker of collagen turnover (C-terminal telopeptide) and prognosis in patients with non- ST -elevation acute coronary syndromes","volume":"8","author":"Zelniker","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2019.11.031_bib57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2019.11.031_bib58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.vph.2018.06.006","article-title":"Hyperglycaemic impairment of PAR2-mediated vasodilation: prevention by inhibition of aortic endothelial sodium-glucose-co-transporter-2 and minimizing oxidative stress","volume":"109","author":"El-Daly","year":"2018","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jacc.2019.11.031_bib59","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2019.11.031_bib60","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2019.11.031_bib61","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/cvr\/cvz004","article-title":"Delayed ischemic contracture onset by Empagliflozin associates with NHE-1 inhibition and is dependent on insulin in isolated mouse hearts","volume":"115","author":"Uthman","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2019.11.031_bib62","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1161\/CIRCULATIONAHA.119.040909","article-title":"Reconceptualization of the molecular mechanism by which sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure events","volume":"140","author":"Packer","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.031_bib63","first-page":"27","article-title":"Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction","volume":"4","author":"Connelly","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Basic Transl Sci"},{"key":"10.1016\/j.jacc.2019.11.031_bib64","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","article-title":"Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction","volume":"18","author":"Zhang","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2019.11.031_bib65","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1210\/jc.2019-00706","article-title":"The effects of dapagliflozin on systemic and renal vascular function display an epigenetic signature","volume":"104","author":"Solini","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2019.11.031_bib66","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/ejhf.1328","article-title":"Empagliflozin directly improves diastolic function in human heart failure","volume":"20","author":"Pabel","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2019.11.031_bib67","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","article-title":"Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes","volume":"17","author":"Matsutani","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2019.11.031_bib68","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","article-title":"Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure","volume":"17","author":"Soga","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2019.11.031_bib69","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.4070\/kcj.2019.0180","article-title":"Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure","volume":"49","author":"Oh","year":"2019","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jacc.2019.11.031_bib70","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2019.11.031_bib71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2019.11.031_bib72","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jacc.2019.11.031_bib73","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2019.11.031_bib74","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cmet.2019.08.015","article-title":"SGLT2 Inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus","volume":"30","author":"Hess","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.jacc.2019.11.031_bib75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","article-title":"SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob(-\/-) mice","volume":"18","author":"Adingupu","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2019.11.031_bib76","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC State-of-the-Art Review","volume":"73","author":"Stahl","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.031_bib77","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2019.11.031_bib78","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.metabol.2019.06.006","article-title":"Effects of dapagliflozin and\/or insulin glargine on beta cell mass and hepatic steatosis in db\/db mice","volume":"98","author":"Omori","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2019.11.031_bib79","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.11.031_bib80","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of increased LDL (low-Density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2019.11.031_bib81","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000499486","article-title":"Consequences of glomerular hyperfiltration: the role of physical forces in the pathogenesis of chronic kidney disease in diabetes and obesity","volume":"143","author":"Chagnac","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.jacc.2019.11.031_bib82","doi-asserted-by":"crossref","first-page":"F399","DOI":"10.1152\/ajprenal.00617.2018","article-title":"Herniation of the tuft with outgrowth of vessels through the glomerular entrance in diabetic nephropathy damages the juxta-glomerular- apparatus","volume":"317","author":"Lowen","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jacc.2019.11.031_bib83","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.031_bib84","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in\u00a0vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.031_bib85","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/CIRCULATIONAHA.119.040326","article-title":"Sodium glucose cotransporter 2 inhibition and the visualization of kidney hemodynamics","volume":"140","author":"Wanner","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.031_bib86","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.kint.2019.02.033","article-title":"Analysis from the EMPA-REG OUTCOME((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics","volume":"96","author":"Mayer","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2019.11.031_bib87","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial","volume":"29","author":"Wanner","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2019.11.031_bib88","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1681\/ASN.2019010064","article-title":"Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program","volume":"30","author":"Neuen","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2019.11.031_bib89","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.11.031_bib90","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.031_bib91","doi-asserted-by":"crossref","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","article-title":"SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1","volume":"316","author":"Novikov","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jacc.2019.11.031_bib92","article-title":"Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects","volume":"7","author":"Wilcox","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2019.11.031_bib93","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcjd.2014.10.013","article-title":"Uric acid as a biomarker and a therapeutic target in diabetes","volume":"39","author":"Lytvyn","year":"2015","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jacc.2019.11.031_bib94","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: Challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2019.11.031_bib95","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000499597","article-title":"Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus","volume":"49","author":"Woods","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2019.11.031_bib96","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium-glucose cotransporter inhibitors and oxidative stress: an update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.jacc.2019.11.031_bib97","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10557-018-6778-x","article-title":"Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes","volume":"32","author":"Birnbaum","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2019.11.031_bib98","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes","volume":"11","author":"Masters","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jacc.2019.11.031_bib99","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2019.11.031_bib100","doi-asserted-by":"crossref","first-page":"F767","DOI":"10.1152\/ajprenal.00565.2018","article-title":"Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy","volume":"317","author":"Lee","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jacc.2019.11.031_bib101","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/dom.13823","article-title":"Effects of dapagliflozin on urinary metabolites in patients with type 2 diabetes","volume":"21","author":"Mulder","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2019.11.031_bib102","doi-asserted-by":"crossref","first-page":"9887","DOI":"10.1038\/s41598-019-46402-6","article-title":"Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death","volume":"9","author":"Shibusawa","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2019.11.031_bib103","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2019.03.432","article-title":"Glucose control and the effect of empagliflozin on kidney outcomes in type 2 diabetes: An analysis from the EMPA-REG OUTCOME Trial","volume":"74","author":"Cooper","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2019.11.031_bib104","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic\u00a0effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2019.11.031_bib105","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s13300-019-00678-z","article-title":"What next after metformin? Thinking beyond glycaemia: are SGLT2 inhibitors the answer?","volume":"10","author":"Evans","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jacc.2019.11.031_bib106","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/ckj\/sfz019","article-title":"Sodium-glucose cotransporter inhibitors: beyond glycaemic control","volume":"12","author":"Vergara","year":"2019","journal-title":"Clin Kidney J"}],"updated-by":[{"DOI":"10.1016\/j.jacc.2020.08.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000}}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719385134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719385134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T07:53:47Z","timestamp":1668671627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719385134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0735109719385134"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter\u00a02\u00a0Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}